Skip to content

Finished goods at other companies

SI-BONE, Inc. logo
SI-BONE, Inc.SIBN
$31.9M+20.8%
Bioventus logo
BioventusBVS
$63.89M-10.3%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$222.3M+11.9%
CONMED logo
CONMEDCNMD
$212.59M+2.3%
Globus Medical logo
Globus MedicalGMED
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$20.9M-36.5%
Gross profit$12.0M-40.9%
Operating income-$2.9M-375%
Net income-$3.1M-5,426%
EPS (diluted)-$0.02

Balance sheet

See full
Cash & equivalents$12.2M+124%
Total debt$15.0M-34.9%
Total equity$48.6M+10.8%
Total assets$78.0M-18.6%

Cash flow

See full
Operating cash flow-$2.1M-265%
CapEx$194.0K-83.7%
Free cash flow-$2.3M-2,753%

Valuation

See full
Market cap$59.05M-32.5%
Enterprise value$61.89M-41.5%
P/E32.3×
P/S0.5×-0.2×

Profitability

See full
Gross margin62.3%+4.2pp
Operating margin4.8%+2.8pp
Net margin1.5%+0.8pp
FCF margin6.4%+4.1pp

Returns & leverage

See full
Return on equity3.9%+2.1pp
Debt / equity0.3×-0.2×
Current ratio3.3×+1.0×

Where this comes from

Reported directly by Xtant Medical Holdings in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoods.

The official record: Xtant Medical Holdings’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xtant Medical Holdings's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xtant Medical Holdings's finished goods?
Xtant Medical Holdings (XTNT) reported finished goods of $20.66M in Q1 2026.
How has Xtant Medical Holdings's finished goods changed year-over-year?
Xtant Medical Holdings's finished goods decreased by 32.2% year-over-year, from $30.46M to $20.66M.
What is the long-term trend for Xtant Medical Holdings's finished goods?
Over 5 years (2020 to 2025), Xtant Medical Holdings's finished goods has grown at a 4.4% compound annual growth rate (CAGR), from $15.92M to $19.78M.
What does finished goods mean?
Completed products ready for sale, valued at the lower of cost or net realizable value.